2849-92-5

Usage

Uses

1H-Benzimidazole-2-carboxylic acid, 1-methyl-, methyl ester (9CI) is used as a chemical intermediate in the synthesis of various organic compounds and pharmaceuticals. Its unique structure and reactivity make it a valuable building block for the development of new molecules with potential applications in different industries.
Used in Pharmaceutical Industry:
1H-Benzimidazole-2-carboxylic acid, 1-methyl-, methyl ester (9CI) is used as a key intermediate for the synthesis of drugs with potential therapeutic applications. Its structure allows for the creation of new molecules that can target specific biological pathways, leading to the development of novel treatments for various diseases.
Used in Chemical Research:
1H-Benzimidazole-2-carboxylic acid, 1-methyl-, methyl ester (9CI) is used as a research compound in the field of organic chemistry. Its unique structure provides opportunities for studying reaction mechanisms, exploring new synthetic routes, and understanding the properties of benzimidazole-based compounds.
Used in Material Science:
1H-Benzimidazole-2-carboxylic acid, 1-methyl-, methyl ester (9CI) is used as a component in the development of new materials with specific properties. Its incorporation into polymers or other materials can lead to the creation of materials with improved characteristics, such as enhanced stability, reactivity, or selectivity.

Upstream product

• 2849-93-6 2-benzimidazolecarboxylic acid 
• 74-88-4 methyl iodide 

Downstream Products

• 1349862-70-9 (1-methyl-1H-benzoimidazol-2-yl)-[3-(3-phenylpyrazin-2-yl)azetidin-1-yl]methanone 
• 20572-01-4 1-methyl-1H-benzo[d]imidazole-2-carboxylic acid 
• 78620-29-8 1-methylbenzimidazole-2-carboxylic acid hydrazide 

Relevant academic research and scientific papers

Benzimidazole-2-carboxylic acid amides and esters: A new structural class of 5-HT3 ligands

A series of novel benzimidazole-2-carboxylic acid amides and esters with a quinuclidine or a tropane moiety were synthesized and evaluated for in vitro affinity for the 5-HT3, 5-HT4 and D2 receptors. Compounds 15a, 13j and 13h exhibited affinity for the 5-HT3 receptor (K(i) = 20.2, 18.4 and 12.7 nM, respectively) and no significant affinity for both 5-HT4 and D2 receptors. The amide-ester replacement did not induce significant changes in the affinity profile. The enantioselectivity for the 5-HT3 receptor was reversed with regard to the zacopride pattern and the (R)-enantiomer 13c showed higher affinity (K(i) = 56.4 nM) than the (S)-enantiomer 13d (K(i) = 242.3 nM). An increment of the steric hindrance around the nitrogen atom at the 1-position of the benzimidazole ring led to an improvement in the affinity. The 5-HT3 receptor antagonist activity of compounds with higher affinity was performed by evaluating the inhibition of the 5-HT induced von Bezold-Jarisch reflex. They displayed moderate 5-HT3 antagonist activity (ED50 = 10.6-29.1 μg/kg i.v.).

INHIBITORS OF MYOCARDIN-RELATED TRANSCRIPTION FACTOR AND SERUM RESPONSE FACTOR (MRTF/SRF)-MEDIATED GENE TRANSCRIPTION AND METHODS FOR USE OF THE SAME

Disclosed herein are inhibitors of gene transcription mediated by myocardin-related transcription factor and serum response factor, or both myocardin-related transcription factor and serum response factor ("MRTF/SRF"), and methods for their use in treating or preventing cancer and fibrosis. In particular, disclosed herein are compounds of Formula (I) and Formula (II), and pharmaceutically acceptable salts thereof: wherein the substituents are as described.